Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : License entities : Glaxosmithkline plc save search
GSK Exercises Option to License Elsie Biotechnologies’ Discovery Platform to Find and Develop Novel Oligonucleotides
Published: 2024-02-14 (Crawled : 13:30) - biospace.com/
GSK | $39.2 -1.01% 1.2M
|
Health Technology
|
| O: 0.89%
H: 0.41%
C: 0.1%
license platform
GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine
Published: 2023-07-20 (Crawled : 11:00) - biospace.com/
GSK | $39.2 -1.01% 1.2M
|
Health Technology
|
| O: 1.19%
H: 0.42%
C: 0.25%
vaccine license grants
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
Published: 2023-05-12 (Crawled : 12:00) - globenewswire.com
GSK | $39.2 -1.01% 1.2M
|
Health Technology
|
| O: 1.6%
H: 0.69%
C: -0.9%
SCYX | $1.47 3.52% 48K
|
Health Technology
|
| O: 1.45%
H: 1.08%
C: -0.36%
brexafemme license agreement
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
Published: 2023-01-05 (Crawled : 09:00) - biospace.com/
GSK | $39.2 -1.01% 1.2M
|
Health Technology
|
| O: -1.28%
H: 0.35%
C: -0.29%
license agreement
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
Published: 2023-01-05 (Crawled : 01:00) - prnewswire.com
GSK | $39.2 -1.01% 1.2M
|
Health Technology
|
| O: -1.28%
H: 0.35%
C: -0.29%
license agreement
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
Published: 2022-11-08 (Crawled : 13:20) - globenewswire.com
GSK | $39.2 -1.01% 1.2M
|
Health Technology
|
| O: 0.53%
H: 1.2%
C: 0.34%
SPRO | $1.52 1.33% 70K
|
Health Technology
|
| O: 6.19%
H: 4.13%
C: -5.34%
license therapeutics agreement
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
Published: 2022-09-22 (Crawled : 07:00) - biospace.com/
GSK | $39.2 -1.01% 1.2M
|
Health Technology
|
| O: -0.71%
H: 2.03%
C: 1.52%
SPRO | $1.52 1.33% 70K
|
Health Technology
|
| O: 148.27%
H: 55.88%
C: 7.84%
license therapeutics agreement
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
Published: 2021-11-22 (Crawled : 23:00) - biospace.com/
GSK | $39.2 -1.01% 1.2M
|
Health Technology
|
| O: -0.38%
H: 0.49%
C: -0.34%
ARWR | $22.57 0.18% 630K
|
Health Technology
|
| O: 2.66%
H: 0.32%
C: -5.1%
license
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
Published: 2021-06-22 (Crawled : 07:00) - prnewswire.com
PFE A | $25.325 -0.37% 25M
|
Health Technology
|
| O: -0.03%
H: 0.71%
C: 0.51%
GSK | $39.2 -1.01% 1.2M
|
Health Technology
|
| O: -0.7%
H: 0.05%
C: -1.06%
HALO M | $37.99 -0.08% 290K
|
Health Technology
|
| O: 0.19%
H: 2.15%
C: 1.89%
collaboration drug license technology drug delivery liver hiv
Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs
Published: 2021-03-18 (Crawled : 12:00) - biospace.com/
GSK | $39.2 -1.01% 1.2M
|
Health Technology
|
| O: 0.17%
H: 0.91%
C: 0.19%
phase 2 unique license multi-year
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
ISPC | $0.4621 116.95% 15M
|
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
PRTG | $0.299 35.17% 120K
|
Mining, Quarrying, and Oil and ...
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
SWVL | $9.64 27.35% 200K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.